Hemophilia
📧 Sign up to get email alerts when something new happens for Hemophilia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-04-29Clinical Trial Update: Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients [Phase 3]
Phase 3 trial evaluating pharmacokinetics, efficacy, and safety of IMMUNATE SD (human plasma-derived Factor VIII concentrate) in Hemophilia …
-
CLINICAL_TRIALS trial_result · 2021-04-27Clinical Trial Update: Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A [Phase 2, Phase 3]
A pediatric pharmacokinetics and efficacy/safety study of recombinant Factor VIII (rAHF-PFM) in Hemophilia A has completed Phase 2 and Phase…
-
CLINICAL_TRIALS trial_result · 2021-04-23Clinical Trial Update: IMMUNINE Pre-Treatment Study [Phase 4]
Phase 4 clinical trial update for IMMUNINE pre-treatment study, completed in Hemophilia B.
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A [Phase 4]
Phase 4 clinical trial update evaluating optimized prophylaxis in patients with severe Hemophilia A.
-
CLINICAL_TRIALS trial_result · 2021-03-01Clinical Trial Update: Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures [Phase 4]
Phase 4 trial update on emicizumab prophylaxis in participants with Hemophilia A undergoing minor surgery; study terminated with results pos…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-02-12FDA Approved: AMINOCAPROIC ACID — Original Application (Biocon Pharma Inc.)
FDA approved Biocon Pharma Inc.'s aminocaproic acid from an original application (ANDA213928), making it an approved generic therapy to trea…
-
FDA approval · 2021-01-26FDA Approved: AMINOCAPROIC ACID — Original Application (Biocon Pharma Inc.)
FDA approves Biocon Pharma Inc.'s aminocaproic acid as an original ANDA, authorizing its marketing as an antifibrinolytic to help control or…
-
CLINICAL_TRIALS trial_result · 2020-11-30Clinical Trial Update: Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors [Phase 2]
Phase 2 study of BAY1093884 in adults with Hemophilia A or B with or without inhibitors was terminated; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-11-10Clinical Trial Update: Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients [Phase 1]
Phase 1 dose-escalation study assessing safety, pharmacokinetics, and pharmacodynamics of ISU304/CB2679d in adults with Hemophilia B; study …
-
CLINICAL_TRIALS trial_result · 2020-10-30Clinical Trial Update: The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients [Phase 4]
Phase 4 clinical trial update evaluating recombinant coagulation factor IX with recombinant albumin (rIX-FP) in severe Hemophilia B patients…
-
CLINICAL_TRIALS trial_result · 2020-10-08Clinical Trial Update: Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A [Phase 2]
Phase 2 clinical trial update on once-daily prophylaxis for youth and young adults with severe Hemophilia A.
-
CLINICAL_TRIALS trial_result · 2020-09-25Clinical Trial Update: Weight-based Dosing in Hemophilia A [Phase 2]
Phase 2 trial investigating weight-based dosing in Hemophilia A has terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2020-09-17Clinical Trial Update: Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy [NA]
A completed clinical trial evaluating platelet-rich plasma intra-articular injections for treating hemophilic arthropathy; results posted in…
-
CLINICAL_TRIALS trial_result · 2020-08-21Clinical Trial Update: Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A [Phase 3]
Phase 3 trial updating safety and efficacy of BAY94-9027 in previously treated male children with Hemophilia A has completed.
-
CLINICAL_TRIALS trial_result · 2020-08-13Clinical Trial Update: An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A [Phase 3]
Phase 3 open-label trial assessing safety and efficacy of replacement factor VIII (rFVIIIFc) in previously untreated males with severe Hemop…
-
CLINICAL_TRIALS trial_result · 2020-07-31Clinical Trial Update: Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B [Phase 3]
A Phase 3 trial evaluating safety and efficacy of rFIXFc in previously untreated males with severe Hemophilia B has completed and posted res…
-
CLINICAL_TRIALS trial_result · 2020-06-16Clinical Trial Update: Study of Ataluren (PTC124) in Hemophilia A and B [Phase 2]
Phase 2 trial of ataluren (PTC124) in Hemophilia A and B was terminated; results posted in 2020.
-
EMA withdrawal · 2020-06-02EMA Withdrawn: Helixate NexGen (octocog alfa) — Bayer AG
EMA has withdrawn Helixate NexGen (octocog alfa) from the market, with the therapeutic area being Hemophilia A.
-
CLINICAL_TRIALS trial_result · 2020-05-29Clinical Trial Update: INdividualized ITI Based on Fviii(ATE) Protection by VWF [Phase 4]
Phase 4 trial update for individualized ITI based on FVIII protection by von Willebrand factor in Hemophilia A patients with inhibitors; tri…
-
CLINICAL_TRIALS trial_result · 2020-05-19Clinical Trial Update: A Gene Therapy Study for Hemophilia B [Phase 2]
Phase 2 gene therapy trial for Hemophilia B completed; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-04-28Clinical Trial Update: Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients. [Phase 4]
Phase 4 trial update assessing long-term safety and efficacy of SCT800 in previously treated Hemophilia A patients.
-
CLINICAL_TRIALS trial_result · 2020-03-24Clinical Trial Update: Prospective Biomarkers of Bone Metabolism in Hemophilia A [Phase 3]
A Phase 3 trial evaluating prospective biomarkers of bone metabolism in individuals with Hemophilia A has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-02-25Clinical Trial Update: Exercise Versus DDAVP in Patients With Mild Hemophilia A [Phase 4]
A Phase 4 clinical trial comparing exercise versus DDAVP in patients with mild Hemophilia A has completed.
-
EMA withdrawal · 2020-02-18EMA Withdrawn: Iblias (octocog alfa) — Bayer AG
The EMA lists Iblias (octocog alfa) as Withdrawn; the therapeutic area is Hemophilia A and the marketing authorization holder is Bayer AG.
-
EMA withdrawal · 2020-02-18EMA Withdrawn: Nonafact (human coagulation factor IX) — Sanquin Plasma Products B.V.
EMA withdrawn the product Nonafact (human coagulation factor IX) for Hemophilia B.